{"id":"NCT02713867","sponsor":"Bristol-Myers Squibb","briefTitle":"A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks","officialTitle":"A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-05-24","primaryCompletion":"2019-07-15","completion":"2022-01-18","firstPosted":"2016-03-21","resultsPosted":"2020-06-22","lastUpdate":"2023-02-14"},"enrollment":363,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Lung Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"Nivolumab","otherNames":[]}],"arms":[{"label":"Nivolumab 240 mg","type":"ACTIVE_COMPARATOR"},{"label":"Nivolumab 480 mg","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to compare PFS (progression-free survival) rate at 6 months and at 1 year after randomization, of Nivolumab 480 mg every 4 weeks with nivolumab 240 mg every 2 weeks in subjects with advanced/metastatic (Stage IIIb/IV) NSCLC (non-Sq and Sq).","primaryOutcome":{"measure":"Progression Free Survival Rate (PFSR) at 6 Months","timeFrame":"At 6 Months","effectByArm":[{"arm":"Nivolumab 480mg","deltaMin":0.76,"sd":null},{"arm":"Nivolumab 240mg","deltaMin":0.79,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":129,"countries":["United States","Australia","Austria","Canada","France","Germany","Italy","Spain"]},"refs":{"pmids":[],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsstudyconnect.com/s/US/English/USenHome","https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":62,"n":178},"commonTop":["Pruritus","Diarrhoea","Fatigue","Arthralgia","Cough"]}}